Ventyx Biosciences Inc [VTYX] stock is trading at $8.51, down -3.30%. An important factor to consider is whether the stock is rising or falling in short-term value. The VTYX shares have gain 7.18% over the last week, with a monthly amount drifted -2.96%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ventyx Biosciences Inc [NASDAQ: VTYX] stock has seen the most recent analyst activity on November 05, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $18 for it. Previously, Wells Fargo upgraded its rating to Overweight on March 12, 2024, and elevated its price target to $16. On March 12, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $12 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $8 on November 07, 2023. Stifel downgraded its rating to a Hold but $6 remained the price target by the analyst firm on November 07, 2023. Oppenheimer downgraded its rating to Perform for this stock on November 07, 2023. In a note dated November 07, 2023, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $46 to $6.
Ventyx Biosciences Inc [VTYX] stock has fluctuated between $0.78 and $10.55 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Ventyx Biosciences Inc [NASDAQ: VTYX] shares were valued at $8.51 at the most recent close of the market. An investor can expect a potential return of 88.01% based on the average VTYX price forecast.
Analyzing the VTYX fundamentals
Gross Profit Margin for this corporation currently stands at 0.03% with Operating Profit Margin at -80.61%, Pretax Profit Margin comes in at -73.62%, and Net Profit Margin reading is -73.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.48 and Total Capital is -0.58. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.35 points at the first support level, and at 8.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.77, and for the 2nd resistance point, it is at 9.03.
Ratios To Look Out For
For context, Ventyx Biosciences Inc’s Current Ratio is 17.86. On the other hand, the Quick Ratio is 17.86, and the Cash Ratio is 2.84.
Transactions by insiders
Recent insider trading involved Nuss John, CHIEF SCIENTIFIC OFFICER, that happened on Apr 02 ’25 when 1887.0 shares were sold. CHIEF SCIENTIFIC OFFICER, Nuss John completed a deal on Dec 27 ’24 to sell 21119.0 shares. Meanwhile, Officer Nuss John bought 21119.0 shares on Dec 27 ’24.
